Recommendations and choices for BRCA mutation carriers at risk for ovarian cancer: A complicated decision

Kelsey Lewis, Karen H. Lu, Amber M. Klimczak, Samuel C. Mok

Research output: Contribution to journalReview article

6 Scopus citations


Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.

Original languageEnglish (US)
Article number57
Issue number2
StatePublished - Feb 21 2018



  • BRCA
  • CA-125
  • Ovarian cancer
  • Risk-reducing surgery
  • Screening guidelines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this